Among the highlights of the September 2017 quarterly performance report for the ERI Scientific Beta indices:
- ERI Scientific Beta offers smart factor indices providing exposure to the six well-known rewarded factors (Mid Cap, Value, High Momentum, Low Volatility, High Profitability and Low Investment) that are also well-diversified in order to reduce the specific risks. This quarter, ending September 30, 2017, the best performing index in the Developed universe among those smart factor indices is the SciBeta Developed Narrow High Factor Exposure High Momentum Diversified Multi-Strategy index with a relative return of 1.62% compared to the broad cap-weighted index, while the SciBeta Developed Narrow High Factor Exposure Mid-Cap Diversified Multi-Strategy index posts the lowest relative return (-2.75%).
- Based on its single smart factor indices, ERI Scientific Beta also offers multi smart factor indices. This quarter, the SciBeta Developed Multi-Beta Multi-Strategy 4-Factor EW index, the SciBeta Developed High Factor Exposure Multi-Beta Multi-Strategy 6-Factor EW index and the SciBeta Developed Multi-Beta Multi-Strategy Max Factor Exposure index post relative returns of -0.65%, -1.23% and -0.46% respectively compared to cap-weighted indices. Year-to-date, the indices post relative returns of -0.05 %, -0.45% and 1.06% respectively compared to cap-weighted indices.
- The Scientific Beta Multi-Beta Multi-Strategy Four-Factor Equal-Weight indices, which were the first multi-factor indices to be offered by ERI Scientific Beta, show an average live annualised outperformance across all Scientific Beta Developed regions of 2.07% over their three-year live track record and an improvement in the Sharpe Ratio of 49.48% compared to their cap-weighted benchmark1.
1The average live outperformance and improvement in Sharpe Ratio across all Scientific Beta developed regions of Scientific Beta Multi-Beta Multi-Strategy Equal Weight indices is 2.07% for the outperformance and 49.48% for the improvement in Sharpe Ratio. This live analysis is based on daily total returns in the period from December 20, 2013 (live date) to September 30, 2017 for all diversified multi-strategy indices that have more than 3 years of track record for all available developed world regions - USA, Eurozone, UK, Developed Europe, Developed Europe ex UK, Japan, Developed Asia Pacific ex Japan, Developed ex UK, Developed ex USA and Developed. The benchmark used is a cap-weighted portfolio of all stocks in the respective Scientific Beta universes.
As part of its policy of transferring know-how to the industry, EDHEC-Risk Institute has set up ERI Scientific Beta. ERI Scientific Beta is an original initiative which aims to favour the adoption of the latest advances in smart beta design and implementation by the whole investment industry. Its academic origin provides the foundation for its strategy: offer, in the best economic conditions possible, the smart beta solutions that are most proven scientifically with full transparency of both the methods and the associated risks.
ERI Scientific Beta, 1 George Street, #15-02, Singapore 049145. For further information, please contact: Carolyn Essid, Tel.: +33 493 187 824, E-mail: [email protected], Web: www.scientificbeta.com.
Find out more about the research conducted by EDHEC-Risk Institute on smart beta and the Scientific Beta indices by following us on Twitter (https://twitter.com/ScientificBeta), LinkedIn (https://www.linkedin.com/company/scientific-beta) and YouTube (https://www.youtube.com/channel/UCRL91F-LvhLPc9M9OD7LQgA).
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/81544063-e250-4ff5-a849-6fa600044e21


Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 



